APA (7th ed.) Citation

Suzuki, K., Nishiwaki, K., Gunji, T., Katori, M., Masuoka, H., & Yano, S. (2020). Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. Cancer Medicine, 9(5), 1694. https://doi.org/10.1002/cam4.2828

Chicago Style (17th ed.) Citation

Suzuki, Kazuhito, Kaichi Nishiwaki, Tadahiro Gunji, Mitsuji Katori, Hidekazu Masuoka, and Shingo Yano. "Elevated Eosinophil Level Predicted Long Time to Next Treatment in Relapsed or Refractory Myeloma Patients Treated with Lenalidomide." Cancer Medicine 9, no. 5 (2020): 1694. https://doi.org/10.1002/cam4.2828.

MLA (9th ed.) Citation

Suzuki, Kazuhito, et al. "Elevated Eosinophil Level Predicted Long Time to Next Treatment in Relapsed or Refractory Myeloma Patients Treated with Lenalidomide." Cancer Medicine, vol. 9, no. 5, 2020, p. 1694, https://doi.org/10.1002/cam4.2828.